Abstract: Systems, methods, and computer program products are provided for segmenting a brain tumor from various MRI sequencing techniques. A plurality of MRI sequences of a head of a patient are received. Each MRI sequence includes a T1-weighted with contrast image, a Fluid Attenuated Inversion Recovery (FLAIR) image, a T1-weighted image, and a T2-weighted image. Each image of the plurality of MRI sequences is registered to an anatomical atlas. A plurality of modified MRI sequences are generated by removing a skull from each image in the plurality of MRI sequences. A tumor segmentation map is determined by segmenting a tumor within a brain in each image in the plurality of modified MRI sequences. The tumor segmentation map is applied to each of the plurality of MRI sequences to thereby generate a plurality of labelled MRI sequences.

Abstract: The present invention provides combinations and methods using same for the treatment of malignancy, particularly a myeloid malignancy such as acute myeloid leukemia (AML), myelodysplastic syndromes (MDS), myeloproliferative neoplasms (MPN), chronic myeloid leukemia (CML), and chronic myelomonocytic leukemia (CMML). The combination may comprise an antibody or antigen-binding fragment thereof that binds to CD70, and an inhibitor of BCL-2. In certain embodiments, the antibody is ARGX-110 (cusatuzumab). In certain embodiments, the BCL-2 inhibitor is venetoclax. In certain embodiments, the combination provides synergistic treatment of AML. The combination may additionally comprise at least one additional anti-cancer agent.

Abstract: Provided are methods and compositions for the treatment of a BCR-ABL1 related disorder (e.g., chronic myelogenous leukemia) using a therapeutic combination of a WNT signaling pathway inhibitor and a BCR-ABL1 tyrosine kinase inhibitor.

Abstract: Systems, methods, and computer program products are provided for segmenting a brain tumor from various MRI sequencing techniques. A plurality of MRI sequences of a head of a patient are received. Each MRI sequence includes a T1-weighted with contrast image, a Fluid Attenuated Inversion Recovery (FLAIR) image, a T1-weighted image, and a T2-weighted image. Each image of the plurality of MRI sequences is registered to an anatomical atlas. A plurality of modified MRI sequences are generated by removing a skull from each image in the plurality of MRI sequences. A tumor segmentation map is determined by segmenting a tumor within a brain in each image in the plurality of modified MRI sequences. The tumor segmentation map is applied to each of the plurality of MRI sequences to thereby generate a plurality of labelled MRI sequences.

Abstract: Systems, methods and apparatus are included that are configured to model microvascular obstruction (MVO) in patients. According to one aspect of the present disclosure, a multi-scale model is configured to mimic myocardial microcirculation of coronary vessels. The model includes collaterals configured to provide alternative pathways possibly bypassing the MVO, and configured to model coronary artery compliance for spatially resolved fluid transport through the coronary vessels. The model is configured to simulate the MVO by increasing flow resistance in at least one of the modelled coronary vessels, or by blocking the at least one of the modelled coronary vessels completely. The model is also configured to mimic behavior of fluid transport in the coronary vessels during diagnostics or treatment, to design and optimize therapy protocols for the MVO.

Abstract: The present invention relates to methods for producing plants with increased fungal resistance, preferably seedling resistance against Northern Corn Leaf Blight. Further provided are methods for introducing, modifying, or modulating at least one wall-associated kinase (WAK) in(to) a plant cell, tissue, organ, or whole plant and thereby causing a reduced synthesis of benzoxazinoid and in turn increased fungal resistance. There are further provided methods to identify and/or modify downstream effector molecules in a WAK signalling cascade. Finally, plant cells, tissues, organs or whole plants having increased fungal resistance and methods using substances to activate signalling pathways in a targeted way are provided.

Abstract: There is disclosed a system for estimating the volume of food on a plate, for example meal, with a mobile device. The system uses a camera and a light pattern projector. Images of the food with and without a projected light pattern on it enable to compute the tridimensional shape and volume, while image segmentation and recognition steps estimate one or more food types in said images. By applying accessible knowledge databases, the carbs content is estimated and the associated insulin bolus doses are provided. Developments comprise coding of the light pattern, different light sources and associated wavelengths, motion compensations, additional optics, estimation of fat content and associated multi-wave boluses. The invention can be implemented in a glucometer or in an insulin pump controller provided with a test strip port or with a mobile phone.

Abstract: There is disclosed a system for estimating the volume of food on a plate, for example meal, with a mobile device. The system uses a camera and a light pattern projector. Images of the food with and without a projected light pattern on it enable to compute the tridimensional shape and volume, while image segmentation and recognition steps estimate one or more food types in said images. By applying accessible knowledge databases, the carbs content is estimated and the associated insulin bolus doses are provided. Developments comprise coding of the light pattern, different light sources and associated wavelengths, motion compensations, additional optics, estimation of fat content and associated multi-wave boluses. The invention can be implemented in a glucometer or in an insulin pump controller provided with a test strip port or with a mobile phone.

Abstract: A cervical implant for dogs includes a plate section for connecting two adjacent vertebral bodies and an intervertebral section which replaces the vertebral disc between the two vertebral bodies, wherein the plate section has at least one receptacle for each vertebral body for fastening the implant.

Abstract: The invention concerns an in vitro method of determining a genotype relating to hereditary nasal parakeratosis (HNPK) in a dog. According to the invention the presence or the absence of a genetic variation in the SUV39H2 gene sequence is indicative of said disorder. The invention also concerns polypeptide based methods for determining said disorder. Further, nucleic acids, polypeptides and antibodies usable in said method are disclosed.

Abstract: The present invention relates to in vitro methods of determining a susceptibility to non-response to a hepatitis C treatment or a susceptibility to spontaneous hepatitis C clearance in a subject infected with hepatitis C.

Abstract: The present invention relates i.a. to vaccines for combating Mycoplasma infection, to mycoplasmal L-?-glycerophosphate oxidase for use in such vaccines, to the use of mycoplasmal L-?-glycerophosphate oxidase for the manufacturing of such vaccines, to methods for the preparation of such vaccines and to diagnostic tests for the discrimination of animals vaccinated with said vaccines and animals vaccinated with whole cell vaccines or animals suffering from field infection.

Abstract: The present invention relates to novel amino acid and nucleic acid sequences of cyclic nucleotide-specific phosphodiesterases from the parasite Leishmania major. The invention also relates to nucleic acid constructs, vectors, and host cells comprising the nucleic acid sequences as well as methods for producing and using the amino acid and nucleic acid sequences. The invention further relates to the use of these sequences, and of antibodies directed against these sequences, in the diagnosis and treatment of disorders related to the infection of Leishmania major, including the identification of compounds that form complexes with the polypeptides and nucleic acids of the present invention.

Abstract: The present invention provides isolated full-length nucleic acid molecules encoding the novel PDE protein of the invention, and methods for uses thereof. The nucleic acid molecules of the invention also include peptide nucleic acids (PNA), and antisense molecules that react with the nucleic acid molecules of the invention. The invention also relates to agonists, antibodies, antagonists or inhibitors of the activity of novel PDE proteins. These compositions are useful for the diagnosis, prevention or treatment of conditions associated with the presence or the deficiency of novel PDE proteins.

Abstract: In one embodiment, a method for treating a cancerous disease is provided which includes characterizing a disease by an overexpression of one or more somatostatin receptors, and exposing the one or more somatostatin receptors to a pharmaceutical composition comprising a somatostatin analogue which binds to the one or more somatostatin receptors.

Abstract: The invention relates to a process and to an apparatus for providing gas for isotopic ratio analysis. According to the invention, a gas is generated from an eluate of a liquid chromatograph (LC). Subsequently, the gas is separated from the eluate. Finally, the gas is fed to an instrument (IRMS) for isotopic ratio analysis.

Abstract: In one embodiment, a composition of somatostatin analogues having the general formula: is provided wherein Z may be absent or present and when present is selected from DOTA- and DTPA-based chelators, NOTA-based chelators, carbonyl compounds, hydrazino nicotinamide, N4-chelators, desferrioxamine, NxSy-chelators, optionally complexed or labeled with a radioisotope, tyrosine for halogenation, a fluorescent dye, or biotin. The composition further provides that L may or may not be present and when present is a linker molecule, X1 is glutamic acid or a symmetric or asymmetric diamino acid containing 3 or 4 consecutive C atoms, X2 is a positively charged natural or unnatural amino acid, an arginine mimic, citrulline, or a neutral amino acid, X3 is phenylalanine, Ala-[3-(2-thienyl)], ?-naphthylalanine, or ?-naphthylalanine, X4 is an aromatic amino acid, X5 is threonine or serine, and X6 is phenylalanine, Ala-[3-(2-thienyl)], ?-naphthylalanine, or ?-naphthylalanine.

Abstract: The present invention provides isolated full-length nucleic acid molecules encoding the novel PDE protein of the invention, and methods for uses thereof. The nucleic acid molecules of the invention also include peptide nucleic acids (PNA), and antisense molecules that react with the nucleic acid molecules of the invention. The invention also relates to agonists, antibodies, antagonists or inhibitors of the activity of novel PDE proteins. These compositions are useful for the diagnosis, prevention or treatment of conditions associated with the presence or the deficiency of novel PDE proteins.

Abstract: A biological evidence collection apparatus provides contact-free drying, storage, identification, and protection against sample switch and contamination of collected biological samples. The apparatus may include the described forensic evidence collection kit which provides a set of tools for the collection and storage of biological evidence. The collection apparatus may also be used as part of a sexual assault evidence collection kit, or a kit for the collection of buccal swabs, and the like.

Abstract: A biological evidence collection apparatus provides contact-free drying, storage, identification, and protection against sample switch and contamination of collected biological samples. The apparatus may include the described forensic evidence collection kit which provides a set of tools for the collection and storage of biological evidence. The collection apparatus may also be used as part of a sexual assault evidence collection kit, or a kit for the collection of buccal swabs, and the like.